History
Documents created during the development process.
Appeal
-
-
-
-
-
Alexion Pharma UK : Response to scrutiny letter (PDF 315 KB)
-
-
Birmingham Children’s Hospital NHS Foundation Trust : Appeal letter (PDF 386 KB)
-
Birmingham Children’s Hospital NHS Foundation Trust : Scrutiny letter (MSWord 58 KB)
-
Birmingham Children’s Hospital NHS Foundation Trust : Response to scrutiny letter (PDF 102 KB)
-
Birmingham Children’s Hospital NHS Foundation Trust : Final scrutiny letter (MSWord 57 KB)
-
-
-
-
-
Salford Royal Hospital NHS Foundation Trust : Appeal letter (MSWord 213 KB)
-
Salford Royal Hospital NHS Foundation Trust : Scrutiny letter (MSWord 57 KB)
-
Salford Royal Hospital NHS Foundation Trust : Response to scrutiny letter (Unknown 244 KB)
-
Salford Royal Hospital NHS Foundation Trust : Final scrutiny letter (MSWord 56 KB)
-
The British Inherited Metabolic Disease Group (BIMDG) : Appeal letter (MSWord 78 KB)
-
The British Inherited Metabolic Disease Group (BIMDG) : Scrutiny letter (MSWord 57 KB)
-
The British Inherited Metabolic Disease Group (BIMDG) : Response to scrutiny letter (Unknown 257 KB)
-
The British Inherited Metabolic Disease Group (BIMDG) : Final scrutiny letter (MSWord 55 KB)
-
Final evaluation determination
Evaluation consultation: 2
Evaluation consultation: 1
Lysosomal acid lipase deficiency - sebelipase alfa: draft scope for consultation (pre-referral) - January 2015
-
Lysosomal acid lipase deficiency - sebelipase alfa: draft scope for consultation (pre-referral) - January 2015
-
Lysosomal acid lipase deficiency - sebelipase alfa: provisional matrix (pre-referral) - January 2015
-
Lysosomal acid lipase deficiency - sebelipase alfa: provisional matrix (pre-referral) - January 2015
-